<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang N</submitter><funding>the Science and Technology Innovation Project of the China Academy of Chinese Medical Sciences</funding><funding>the Independent Topic Selection Research Project of the Institute of Basic Theory of Chinese Medicine, China Academy of Chinese Medical Sciences</funding><funding>the National Natural Science Foundation of China Youth Program</funding><funding>Science and Technology Innovation Project, Chinese Academy of Traditional Chinese Medicine</funding><pagination>554</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12899346</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(3)</volume><pubmed_abstract>Rheumatoid arthritis involves chronic synovitis and immune-metabolic dysregulation, highlighting a need for multi-target therapies that jointly modulate metabolism and inflammation. We developed glycyrrhiza protein-paeoniflorin self-assembled nanoparticles (GP-PF NPs) and investigated their anti-arthritic mechanism in adjuvant-induced arthritis (AIA) mice, using UHPLC-Orbitrap-MS-based metabolomics. Male C57BL/6 mice (&lt;i>n&lt;/i> = 42) were assigned to the control, model, GP-PF NPs, paeoniflorin, glycyrrhiza protein, physical mixture, and celecoxib groups. All groups except controls received complete Freund's adjuvant, and treatments were given intraperitoneally for 10 days. GP-PF NPs produced the greatest reduction in paw thickness versus the model (&lt;i>p&lt;/i> &lt; 0.0001) and outperformed all ot</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pubmed_title>A UHPLC-Orbitrap-MS Metabolomics Strategy Reveals Glycerophospholipid Metabolic Remodeling Is Associated with the Anti-Arthritic Effect of Glycyrrhiza Protein-Paeoniflorin Nanoparticles via PI3K/AKT/NLRP3 Axis.</pubmed_title><pmcid>PMC12899346</pmcid><funding_grant_id>(KYG-202409</funding_grant_id><funding_grant_id>81403282</funding_grant_id><funding_grant_id>YZX-202232</funding_grant_id><funding_grant_id>CI2021A0O108</funding_grant_id><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Bai D</pubmed_authors><pubmed_authors>Huo M</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Li C</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Zhang N</pubmed_authors></additional><is_claimable>false</is_claimable><name>A UHPLC-Orbitrap-MS Metabolomics Strategy Reveals Glycerophospholipid Metabolic Remodeling Is Associated with the Anti-Arthritic Effect of Glycyrrhiza Protein-Paeoniflorin Nanoparticles via PI3K/AKT/NLRP3 Axis.</name><description>Rheumatoid arthritis involves chronic synovitis and immune-metabolic dysregulation, highlighting a need for multi-target therapies that jointly modulate metabolism and inflammation. We developed glycyrrhiza protein-paeoniflorin self-assembled nanoparticles (GP-PF NPs) and investigated their anti-arthritic mechanism in adjuvant-induced arthritis (AIA) mice, using UHPLC-Orbitrap-MS-based metabolomics. Male C57BL/6 mice (&lt;i>n&lt;/i> = 42) were assigned to the control, model, GP-PF NPs, paeoniflorin, glycyrrhiza protein, physical mixture, and celecoxib groups. All groups except controls received complete Freund's adjuvant, and treatments were given intraperitoneally for 10 days. GP-PF NPs produced the greatest reduction in paw thickness versus the model (&lt;i>p&lt;/i> &lt; 0.0001) and outperformed all ot</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-07T03:10:36.092Z</modification><creation>2026-07-07T03:08:33.528Z</creation></dates><accession>S-EPMC12899346</accession><cross_references><pubmed>41683531</pubmed><doi>10.3390/molecules31030554</doi></cross_references></HashMap>